• SPX
  • $5,859.85
  • 0.77 %
  • $44.82
  • DJI
  • $43,065.22
  • 0.47 %
  • $201.36
  • N225
  • $40,130.18
  • 1.32 %
  • $524.45
  • FTSE
  • $8,292.66
  • 0.47 %
  • $39.01
  • IXIC
  • $18,502.69
  • 0.87 %
  • $159.75
Cue Biopharma, Inc. (CUE) Stock Price, News & Analysis

Cue Biopharma, Inc. (CUE) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.21

-$0.02

(-1.63%)

Day's range
$1.17
Day's range
$1.24
50-day range
$0.45
Day's range
$1.46
  • Country: US
  • ISIN: US22978P1066
52 wk range
$0.45
Day's range
$3.25
  • CEO: Mr. Daniel R. Passeri J.D., M.Sc.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -12.89
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (CUE)
  • Company Cue Biopharma, Inc.
  • Price $1.21
  • Changes Percentage (-1.63%)
  • Change -$0.02
  • Day Low $1.17
  • Day High $1.24
  • Year High $3.25

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/07/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $6.00
  • High Stock Price Target $7.00
  • Low Stock Price Target $2.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.07
  • Trailing P/E Ratio -1.38
  • Forward P/E Ratio -1.38
  • P/E Growth -1.38
  • Net Income $-50,733,000

Income Statement

Quarterly

Annual

Latest News of CUE

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.